Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$4.54
+0.1%
$4.39
$3.53
$8.59
$428.80M1.731.61 million shs2.44 million shs
Neogen Corporation stock logo
NEOG
Neogen
$9.31
$9.12
$4.56
$11.43
$2.03B1.82.40 million shs5.07 million shs
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
$13.67
$12.80
$9.92
$35.58
$932.17M0.771.58 million shs2.15 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
+3.74%-1.86%+28.00%-0.79%-10.37%
Neogen Corporation stock logo
NEOG
Neogen
+4.26%+0.76%+11.50%+11.36%+86.57%
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
+4.11%-2.98%+20.12%-10.30%-51.75%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$4.54
+0.1%
$4.39
$3.53
$8.59
$428.80M1.731.61 million shs2.44 million shs
Neogen Corporation stock logo
NEOG
Neogen
$9.31
$9.12
$4.56
$11.43
$2.03B1.82.40 million shs5.07 million shs
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
$13.67
$12.80
$9.92
$35.58
$932.17M0.771.58 million shs2.15 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
+3.74%-1.86%+28.00%-0.79%-10.37%
Neogen Corporation stock logo
NEOG
Neogen
+4.26%+0.76%+11.50%+11.36%+86.57%
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
+4.11%-2.98%+20.12%-10.30%-51.75%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2.00
Hold$6.5043.05% Upside
Neogen Corporation stock logo
NEOG
Neogen
2.17
Hold$10.6714.57% Upside
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
1.67
Reduce$14.888.81% Upside

Current Analyst Ratings Breakdown

Latest QDEL, NEOG, and MYGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/15/2026
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
UpgradeStrong SellHold
6/4/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
UpgradeSell (E+)Sell (D-)
5/18/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
DowngradeSell (D-)Sell (E+)
5/7/2026
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
Reiterated RatingNeutral$12.00
5/7/2026
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
DowngradeBuyHold$35.00 ➝ $12.50
5/6/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Lower Price TargetHold$7.00 ➝ $6.00
5/6/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
Lower Price TargetEqual Weight$6.00 ➝ $5.50
5/6/2026
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
Lower Price TargetNeutral$30.00 ➝ $13.00
4/21/2026
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
Reiterated RatingSell (E+)
4/13/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
UpgradeHold
4/10/2026
Neogen Corporation stock logo
NEOG
Neogen
Reiterated RatingSell (D-)
(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$824.50M0.52$3.76 per share1.21$3.95 per share1.15
Neogen Corporation stock logo
NEOG
Neogen
$894.66M2.27$5.78 per share1.61$9.54 per share0.98
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
$2.73B0.34$18.99 per share0.72$28.27 per share0.48
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$365.90M-$4.30N/AN/AN/A-48.24%-8.51%-4.48%8/4/2026 (Estimated)
Neogen Corporation stock logo
NEOG
Neogen
-$1.09B-$2.80N/A42.324.17-69.93%2.35%1.46%8/4/2026 (Estimated)
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
-$1.13B-$17.82N/A5.49N/A-45.57%4.25%1.56%7/29/2026 (Estimated)

Latest QDEL, NEOG, and MYGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2026Q1 2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$0.06-$0.09-$0.03-$0.36$202.42 million$200.40 million
5/5/2026Q1 2026
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
$0.37-$0.04-$0.41-$1.35$665.23 million$619.80 million
4/9/2026Q3 2026
Neogen Corporation stock logo
NEOG
Neogen
$0.04$0.09+$0.05-$0.08$204.62 million$211.20 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
N/AN/AN/AN/AN/A
Neogen Corporation stock logo
NEOG
Neogen
N/AN/AN/AN/AN/A
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
0.36
2.40
2.19
Neogen Corporation stock logo
NEOG
Neogen
0.38
3.92
2.84
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
1.33
1.43
0.80

Institutional Ownership

CompanyInstitutional Ownership
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
99.02%
Neogen Corporation stock logo
NEOG
Neogen
96.73%
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
99.00%

Insider Ownership

CompanyInsider Ownership
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
1.90%
Neogen Corporation stock logo
NEOG
Neogen
0.55%
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
1.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2,70094.45 million92.65 millionOptionable
Neogen Corporation stock logo
NEOG
Neogen
2,110217.67 million216.48 millionOptionable
QuidelOrtho Corporation stock logo
QDEL
QuidelOrtho
6,50068.19 million67.44 millionOptionable

Recent News About These Companies

When Blood Compatibility Becomes a Pregnancy Risk
QuidelOrtho (QDEL) Receives a Sell from J.P. Morgan

New MarketBeat Followers Over Time

Media Sentiment Over Time

Myriad Genetics stock logo

Myriad Genetics NASDAQ:MYGN

$4.54 +0.00 (+0.09%)
Closing price 06/18/2026 03:59 PM Eastern
Extended Trading
$4.54 0.00 (-0.09%)
As of 06/18/2026 05:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Neogen stock logo

Neogen NASDAQ:NEOG

$9.31 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$9.18 -0.13 (-1.35%)
As of 06/18/2026 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods. The segment offers its products primarily to milling and grain, meat and poultry, prepared foods and ingredients, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products, and genomics testing services marketed through veterinarians, retailers, livestock producers, and animal health product distributors, for the animal safety market. The segment offers its products for companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

QuidelOrtho stock logo

QuidelOrtho NASDAQ:QDEL

$13.67 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$13.80 +0.13 (+0.91%)
As of 06/18/2026 05:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.